Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors

Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug–drug interactions (DDI) may h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannady, Ellen A, Wang, Ming-Dauh, Friedrich, Stuart, Rehmel, Jessica L F, Yi, Ping, Small, David S, Zhang, Wei, Suico, Jeffrey G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618649/
https://www.ncbi.nlm.nih.gov/pubmed/26516590
http://dx.doi.org/10.1002/prp2.179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618649/
https://www.ncbi.nlm.nih.gov/pubmed/26516590
http://dx.doi.org/10.1002/prp2.179

Ejemplares similares